Tenax Therapeutics provides levosimendan clinical trial update
Tenax Therapeutics provided an update on its on-going clinical trial of levosimendan. Tenax is conducting a multi-center, double-blind placebo controlled Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction, or PH-HFpEF. The study is also known as the HELP trial. There are currently 12 activated sites, with an additional three sites expected to be activated over the next few weeks, which the company believes will be sufficient to fully enroll the trial. Eight patients, up from three at the end of June, are currently enrolled out of the targeted 36 patients. Three of the eight patients have completed the initial 6-week HELP protocol and have rolled over into the 2-year extension phase.